论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
下一代测序揭示了具有不同的 EGFR 19 缺失或 EGFR 20 插入或 EZR-ROS1 融合的驱动程序改变的同步三边形肺腺癌病例
Authors Zhang X, Feng J, Su X, Lei Y, Wu W, Cheng X
Received 23 September 2020
Accepted for publication 21 November 2020
Published 9 December 2020 Volume 2020:13 Pages 12667—12671
DOI https://doi.org/10.2147/OTT.S283617
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Nicola Silvestris
Objective: Synchronous multiple primary lung cancer (SMPLC) has a reported occurrence from 0.5% to 2% in lung cancer, and the surgical treatment and prognosis were quite diverse. With the discovery of driver mutations in lung adenocarcinoma (ADC), next-generation sequencing (NGS) would provide an explicit answer to the key question, whether individual tumors represent intrapulmonary metastases or independent tumors. Here, we reported a 64-year-old female diagnosed with a synchronous trilateral early-stage ADC with distinct driver alterations.
Materials and Methods: NGS test targeting 31 cancer-relevant genes and amplification RNA sequencing (if gene fusion was found on DNA level) were performed on the surgical tumor tissue.
Results: A 64-year-old Chinese female never smoker was found with one nodule in the right upper lobe and two nodules in the right middle lobe through chest computed tomography. The lesions were resected through video-assisted thoracic surgery and diagnosed with stage IA ADC, T1N0M0, in the postoperative pathology. NGS detected three independent driver mutations in three primary sites, respectively, EGFR 19del, EGFR 20ins and ROS1 fusion.
Conclusion: This is the first report of a synchronous trilateral early-stage ADC with distinct driver alterations. All individual tumors were independent identified by NGS methodology, which had provided a clear answer to the key question of SMPLC in this case and should be used as a routine genetic test to explore fully pathological diagnosis and more comprehensive oncogenesis information in the early-stage ADC clinical prevention.
Keywords: synchronous multiple primary lung cancer, lung adenocarcinoma, NGS, EGFR mutation, ROS1 fusion